Targeted siRNA Nanoparticles Promote Neutrophil Cuproptosis to Alleviate Pseudomonas aeruginosa Lung Injury

Study Background and Research Question

Pseudomonas aeruginosa (PA), a metabolically flexible Gram-negative bacterium, is a leading cause of severe respiratory tract infections, particularly in immunocompromised individuals. Clinical management is increasingly complicated by multidrug-resistant PA strains, necessitating novel therapeutic approaches that go beyond conventional antibiotics. Neutrophils, the first responders in innate immunity, are central to early defense but can also contribute to lung injury if their death and activation are dysregulated. While various forms of neutrophil cell death—including NETosis and pyroptosis—have been implicated in PA pathogenesis, the role of cuproptosis, a copper-dependent and recently characterized cell death pathway, had not been explored in this context. The reference study (Zhang et al., 2026) addresses whether modulating neutrophil cuproptosis could mitigate PA-induced lung damage and elucidates the underlying molecular mechanisms.

Key Innovation from the Reference Study

The study's primary innovation lies in the development and preclinical validation of a hyaluronic acid (HA)-coated peptide nanoparticle platform for targeted delivery of small interfering RNA (siRNA) against Tudor domain-containing protein 9 (TDRD9). TDRD9 was identified as a pivotal regulator of neutrophil survival during PA infection. By silencing TDRD9 specifically in neutrophils, the researchers achieved enhanced induction of cuproptosis, leading to reduced pulmonary inflammation and improved bacterial clearance. This approach represents a mechanistically informed strategy that leverages extracellular matrix (ECM) components—specifically, sodium hyaluronate—as both a biocompatible nanoparticle coating and a targeting moiety for immune cell modulation.

Methods and Experimental Design Insights

The authors employed an integrative experimental workflow that spanned patient-derived samples, murine infection models, and human lung organoids. Key methodological steps included:

• RNA sequencing of bronchoalveolar lavage (BAL) fluid-derived neutrophils from PA-infected patients to identify upregulated targets (notably TDRD9).
• Design and synthesis of HA-coated peptide nanoparticles encapsulating TDRD9-targeting siRNA (HA-si-TDRD9 NPs).
• In vivo adoptive transfer of TDRD9-silenced neutrophils into neutrophil-depleted mice, followed by PA infection and assessment of lung inflammation, edema, and bacterial load.
• Mechanistic analysis of the PD-L1/CD80/MAPK axis in neutrophil cuproptosis, using molecular and immunohistochemical assays.
• Validation of anti-inflammatory and antibacterial effects in human lung organoid models exposed to PA and HA-si-TDRD9 NPs.

The use of sodium hyaluronate as a nanoparticle coating was critical for cellular targeting and stability, reflecting a broader trend in nanomedicine to exploit ECM components for drug delivery and immune modulation (see related review).

Core Findings and Why They Matter

Several key results emerged from the study:

• TDRD9 is upregulated in pulmonary neutrophils during PA infection, and its expression correlates with inflammatory severity.
• Silencing TDRD9 with HA-siRNA nanoparticles promotes neutrophil cuproptosis by relieving TDRD9-mediated upregulation of PD-L1 and subsequent activation of the CD80/MAPK signaling pathway.
• Neutrophil-specific TDRD9 knockdown reduces lung inflammation, edema, and bacterial growth in both mouse models and human lung organoids, supporting the translational relevance of this approach (see internal highlight).

Mechanistically, the study demonstrates that TDRD9 suppresses neutrophil cuproptosis by regulating PD-L1 expression and downstream p38 MAPK signaling. By targeting this pathway, the HA-si-TDRD9 nanoparticle approach not only enhances bacterial clearance but also limits excessive neutrophil accumulation and secondary tissue injury. These results underscore the therapeutic potential of modulating regulated cell death pathways in infectious lung disease, while also highlighting sodium hyaluronate as a functional extracellular matrix component in advanced delivery systems.

Comparison with Existing Internal Articles

Internal literature on hyaluronic acid sodium salt (sodium hyaluronate) provides important context for the translational leap achieved in the reference study. For example, a recent review details the roles of high molecular weight hyaluronic acid in extracellular matrix biology, signal modulation, and its application as a PI3K-Akt signaling modulator and carrier in nanoparticle-mediated delivery. This aligns with the reference paper’s use of sodium hyaluronate to facilitate targeted siRNA delivery and immune modulation. Another article, "Hyaluronic Acid Sodium Salt: From ECM Mechanisms to Nanomedicine", specifically discusses the pivotal function of sodium hyaluronate in next-generation biopolymer-based nanotherapies, referencing the same HA-coated siRNA strategies for infection and immune modulation. Together, these resources illustrate the progression from foundational ECM biochemistry to practical, disease-targeted nanomedicine.

Limitations and Transferability

While the preclinical results are compelling, several limitations must be acknowledged. First, the study’s findings are based on murine models and human organoid systems, which, although informative, may not fully recapitulate the complexity of human lung physiology and immune responses in vivo. Second, the long-term safety and biodistribution of HA-siRNA nanoparticles require further investigation before clinical translation. Additionally, the mechanistic focus on neutrophil cuproptosis, while novel, does not address potential effects on other immune cell populations or on the broader tissue microenvironment. The transferability of the HA-siRNA nanoparticle platform to other infectious or inflammatory settings remains promising but unproven, warranting future studies.

Protocol Parameters

• siRNA nanoparticle formulation: HA (high molecular weight sodium hyaluronate) used as a nanoparticle coating for neutrophil targeting. Literature supports using nanomolar to micromolar concentrations for in vitro work; actual dosing optimized per model system (internal review).
• Neutrophil depletion and adoptive transfer: Neutrophil-depleted mice received 1-2 million TDRD9-silenced neutrophils intravenously prior to PA infection.
• Infection model: PA administered intratracheally; endpoints included lung histology, edema, flow cytometry for neutrophil markers, and bacterial burden quantification.
• Human lung organoid assays: Organoids co-cultured with PA and HA-si-TDRD9 NPs; outcomes assessed by apoptosis, cytokine expression, and bacterial counts.
• Storage and handling: Hyaluronic acid sodium salt solutions are best prepared fresh and used immediately, as long-term storage is not recommended (product information).

Research Support Resources

For experimentalists seeking to recapitulate or extend these findings, Hyaluronic acid sodium salt (SKU B8382) from APExBIO offers a high molecular weight, well-characterized extracellular matrix biopolymer suitable for nanoparticle coating and cell-based assays. Its established use as a shock absorption polymer and joint lubrication biopolymer, as well as a carrier for nucleic acid delivery, aligns with the requirements of advanced infection and immune modulation studies. For further practical guidance on protocol design and ECM modeling, researchers may reference scenario-driven workflows detailed in internal resources such as this laboratory Q&A article.